
Ruminations about biotech and drug development - one overly earnest blog post at a time.
| Platform | Pricing | Freemium | Publishes | Weekly | |
|---|---|---|---|---|---|
| Issues | 37 | Founded | 6 years ago | Last Issue | 4 months ago |
| Active | |||||

Some thoughts on Peter Thiel's view of the beta-amyloid hypothesis as a lens for understanding the messy, slow cost of figuring out how to make drugs for complex diseases.
Last May, during a conversation with Ross Douthat, Peter Thiel turn...
Disclosure: This profile was commissioned by Axiom Bio. The company provided access to its offices, team, and partner meetings and reviewed drafts for factual accuracy.
Consider the hepatocyte. It is a polyhedral thing, roughly twen...
You know what’s a fun way to spend a morning? Calculating whether a fictional chemistry teacher’s cancer would be treatable with modern targeted therapy and whether his employer health plan would cover it. I have done this. Let me tell you...
In September 2021, Bristol Myers Squibb discontinued development of pegbelfermin, a PEGylated version of a hormone called FGF21, after spending years and probably hundreds of millions of dollars testing it in patients with liver disease. Th...
Patent law rests on a simple covenant: inventors reveal their secrets, and society grants them temporary monopolies in return. But some companies want the monopoly without the showing. They want the treasure. They don’t want to draw the map...
Subscribers, engagement, traffic and sponsorship for Alex Kesin's Pharmacopoeia.
| Subscribers | Engagement | 74 | Monthly Web Visits | ||
|---|---|---|---|---|---|
| Accepts Sponsors | Estimated Cost per Ad | ||||
Where Alex Kesin's Pharmacopoeia ranks on Google, and how much search traffic it brings in.
| Ranked Keywords | 26 | Monthly Search Traffic | Top Keywords |
|---|
The writers behind this newsletter.
I write about drugs (the legal kind).
You can find recent issues that have been published by Alex Kesin's Pharmacopoeia on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
To see how many people subscribe to Alex Kesin's Pharmacopoeia, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
Newsletter advertising can be extremely effective when it's done right. Before you pitch Alex Kesin's Pharmacopoeia as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact Alex Kesin's Pharmacopoeia using the contact information provided and ask for a copy of their media kit.
Scroll up to where it says Related Newsletters to see other publications like Alex Kesin's Pharmacopoeia. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.